Search
Amphotericin B
go.drugbank.com/drugs/DB00681ApprovedInvestigationalAmphotericin B shows a high order of in vitro activity against many species of fungi. … Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by
Products: AMPHOLIP Injection 50mg/10ml, AMPHOTRET FOR INJECTION USP 50MGErgoloid mesylate
go.drugbank.com/drugs/DB01049Approved[A32914] The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued. … [L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA.
Omidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigational[L46048,L46058] In December 2025, the indication was expanded to include adults and pediatric patients six years and older with severe aplastic anemia (SAA). [L46048,L54688] … [A258958] In April 2023, the FDA approved the use of omidubicel in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative
Donidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin. … [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]
Lofexidine
go.drugbank.com/drugs/DB04948ApprovedInvestigational[A33084] It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. … [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794]
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigational[L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.1[L45419]
Enzacamene
go.drugbank.com/drugs/DB11219ApprovedWhile its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada.
Mixtures: But First WatermRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.
Azelastine
go.drugbank.com/drugs/DB00972ApprovedInvestigationalcombination with fluticasone propionate as a nasal spray marketed under the trade name Dymista™, which is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.